Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Recent Analyst Ratings for $ADCT

$ADCT Press Releases

$ADCT Analyst Ratings

$ADCT Financials

$ADCT FDA approvals

$ADCT SEC Filings

$ADCT Insider Trading

$ADCT Insider Purchases

$ADCT Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stephens initiated coverage on ADC Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on ADC Therapeutics

Guggenheim initiated coverage on ADC Therapeutics with a new price target

Live finance-specific insights

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

SEC Form DEF 14A filed by ADC Therapeutics SA

SEC Form DEFA14A filed by ADC Therapeutics SA

SEC Form PRE 14A filed by ADC Therapeutics SA

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Mallik Ameet covered exercise/tax liability with 26,758 shares, decreasing direct ownership by 2% to 1,552,247 units (SEC Form 4)

Chief Legal Officer Graham Peter J was granted 220,000 shares, increasing direct ownership by 117% to 408,542 units (SEC Form 4)

Chief Medical Officer Zaki Mohamed was granted 230,000 shares, increasing direct ownership by 99% to 462,888 units (SEC Form 4)

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

This live feed shows all institutional transactions in real time.

11/13/24 8:58:56 AM ET

$ADCT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADCT alert in real time by email

SC 13G/A 1 d882324dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

ADC THERAPEUTICS SA

(Name of Issuer)

Common Shares

(Title of Class of Securities)

H0036K147

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

Taylor H. Wilson, Esq.

Haynes and Boone, LLP

2801 N Harwood St, Suite 2300

Dallas, Texas 75201

(214) 651-5000

SCHEDULE 13G

CUSIP No. H0036K147

(1)

Based upon 96,689,617 shares of common shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the U.S. Securities and Exchange Commission (the “SEC”) on November 7, 2024.

SCHEDULE 13G

CUSIP No. H0036K147

(1)	Based upon 96,689,617 shares of common shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 7, 2024.

SCHEDULE 13G

CUSIP No. H0036K147

(1)	Based upon 96,689,617 shares of common shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 7, 2024.

SCHEDULE 13G

CUSIP No. H0036K147

(1)	Based upon 96,689,617 shares of common shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 7, 2024.

SCHEDULE 13G

CUSIP No. H0036K147

(1)	Based upon 96,689,617 shares of common shares outstanding as of November 1, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, that was filed by the Issuer with the SEC on November 7, 2024.

Item 1.

(a)

Name of Issuer:

ADC Therapeutics SA (the “Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

Item 2.

(a)

Name of Person Filing:

This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership (“Prosight Management”), Prosight Fund, LP, a Delaware limited partnership (“Prosight Fund”), Prosight Plus Fund, LP, a Delaware limited partnership (“Prosight Plus Fund”), Prosight Partners, LLC, a Delaware limited liability company (“Prosight Partners”), and W. Lawrence Hawkins (collectively referred herein as “Reporting Persons”). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners. Prosight Fund, Prosight Plus Fund and the Managed Accounts are the record and direct beneficial owner of the Common Shares covered by this statement. Prosight Fund disclaims beneficial ownership of the Common Shares held by the Managed Accounts and the Common Shares held by Prosight Plus Fund. Prosight Plus Fund disclaims beneficial ownership of the Common Shares held by the Managed Accounts and the Common Shares held by Prosight Fund.

Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

(b)

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.

(c)

Citizenship:

See Item 4 on the cover page(s) hereto.

(d)

Title and Class of Securities:

Common Shares, par value CHF 0.08 per share (“Common Shares”)

(e)

CUSIP No.:

H0036K147

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act;

(b)	☐	Bank as defined in Section 3(a)(6) of the Act;

(c)	☐	Insurance company as defined in Section 3(a)(19) of the Act;

(d)	☐	Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)	☐	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)	☐	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4. Ownership

(a)

Amount Beneficially Owned as of the time of filing: See Item 9 on the cover pages(s) hereto.

(b)

Percent of Class as of the time of filing: See Item 11 on the cover page(s) hereto.

(c)

As of the time of filing, number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

(ii)

Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

(iii)

Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

(iv)

Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following [ ].

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

Not applicable

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Not applicable

Item 8.

Identification and classification of members of the group.

Not applicable

Item 9.

Notice of Dissolution of Group.

Not applicable

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 13, 2024


PROSIGHT MANAGEMENT, LP

By:		Prosight Partners, LLC
Its:		General Partner

By:		/s/ W. Lawrence Hawkins
Name:		W. Lawrence Hawkins
Title:		Sole Manager

PROSIGHT FUND, LP

By:		Prosight Management, LP
Its:		General Partner

By:		Prosight Partners, LLC
Its:		General Partner

By:		/s/ W. Lawrence Hawkins
Name:		W. Lawrence Hawkins
Title:		Sole Manager

PROSIGHT PLUS FUND, LP

By:		Prosight Management, LP
Its:		General Partner

By:		Prosight Partners, LLC
Its:		General Partner

By:		/s/ W. Lawrence Hawkins
Name:		W. Lawrence Hawkins
Title:		Sole Manager

PROSIGHT PARTNERS, LLC

By:		/s/ W. Lawrence Hawkins
Name:		W. Lawrence Hawkins
Title:		Sole Manager

W. LAWRENCE HAWKINS

/s/ W. Lawrence Hawkins

EXHIBIT INDEX


Exhibit		Description of Exhibit

99.1		Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on April 17, 2023, by the Reporting Persons with the SEC).

Get the next $ADCT alert in real time by email

Date	Price Target	Rating	Analyst
11/8/2024	$6.00	Overweight	Stephens
5/30/2024		Overweight	Cantor Fitzgerald
3/28/2024	$11.00	Buy	Guggenheim
8/10/2023		Underweight → Neutral	JP Morgan
4/24/2023	$7.00 → $2.00	Neutral → Underperform	BofA Securities
12/6/2022	$12.00	Overweight	CapitalOne
11/9/2022	$14.00 → $7.00	Buy → Neutral	BofA Securities
9/21/2022	$5.00	Overweight	JP Morgan

Names of Reporting Persons

Prosight Management, LP

Check the appropriate box if a member of a Group (see instructions)

(a) ☐ (b) ☒

Sec Use Only

Citizenship or Place of Organization

Delaware